Liu J, Ayada I, Zhang X, Wang L, Li Y, Wen T et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese adults. Clin Gastroenterol Hepatol. 2022;20:e573–e582

Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH et al. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hep Intl. 2020;14:889–919

Article  Google Scholar 

Zheng KI, Fan JG, Shi JP, Wong VW, Eslam M, George J et al. From NAFLD to MAFLD: a "redefining" moment for fatty liver disease. Chin Med J. 2020;133:2271–2273

Article  Google Scholar 

Méndez-Sánchez N, Bugianesi E, Gish RG, Lammert F, Tilg H, Nguyen MH et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol. 2022;7:388–390

Méndez-Sánchez N, Díaz-Orozco L, Córdova-Gallardo J. Redefinition of fatty liver disease from NAFLD to MAFLD raised disease awareness: Mexican experience. J Hepatoly. 2021;75:221–222

Article  Google Scholar 

Eslam M, Sanyal AJ, George J. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease.Gastroenterol. 2020;158:1999-2014.e1991

CAS  Article  Google Scholar 

Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J et al. Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. J Hepatol. 2018;69:896–904

Article  Google Scholar 

Zheng KI, Eslam M, George J, Zheng MH. When a new definition overhauls perceptions of MAFLD related cirrhosis care. Hepatobiliary Surg Nutr. 2020;9:801–804

Article  Google Scholar 

Rios RS, Zheng KI, Zheng MH. Non-alcoholic steatohepatitis and risk of hepatocellular carcinoma. Chin Med J. 2021;134:2911–2921

Wang TY, Wang RF, Bu ZY, Targher G, Byrne CD, Sun DQ et al. Association of metabolic dysfunction-associated fatty liver disease with kidney disease. Nat Rev Nephrol. 2022;18:259–268

Article  Google Scholar 

Fouad Y, Gomaa A, Semida N, Ghany WA, Attia D. Change from NAFLD to MAFLD increases the awareness of fatty liver disease in primary care physicians and specialists. J Hepatol. 2021;74:1254–1256

Article  Google Scholar 

Zheng KI, Zheng MH. The uprising of metabolic dysfunction-associated fatty liver disease (MAFLD) in acute-on-chronic liver failure (ACLF). Hepatobiliary Surg Nutr. 2021;10:857–859

Article  Google Scholar 

Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatol. 2015;61:1547–1554

CAS  Article  Google Scholar 

Shah AG, Lydecker A, Murray K, Tetri BN, Contos MJ, Sanyal AJ. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7:1104–1112

CAS  Article  Google Scholar 

Zheng KI, Sun DQ, Jin Y, Zhu PW, Zheng MH. Clinical utility of the MAFLD definition. J Hepatol. 2021;74:989–991

Article  Google Scholar 

Wu XX, Zheng KI, Boursier J, Chan WK, Yilmaz Y, Romero-Gómez M et al. acNASH index to diagnose nonalcoholic steatohepatitis: a prospective derivation and global validation study. EClinicalMedicine. 2021;41:101145

Article  Google Scholar 

Vilar-Gomez E, Chalasani N. Non-invasive assessment of non-alcoholic fatty liver disease: Clinical prediction rules and blood-based biomarkers. J Hepatol. 2018;68:305–315

CAS  Article  Google Scholar 

Castera L, Friedrich-Rust M, Loomba R. Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease. Gastroenterol. 2019;156:1264-1281.e1264

Article  Google Scholar 

Younossi ZM, Gramlich T, Liu YC, Matteoni C, Petrelli M, Goldblum J et al. Nonalcoholic fatty liver disease: assessment of variability in pathologic interpretations. Mod pathol 1998;11:560–565

Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterol. 2005;128:1898–1906

Article  Google Scholar 

Tang LJ, Ma HL, Eslam M, Wong GL, Zhu PW, Chen SD et al. Among simple non-invasive scores, Pro-C3 and ADAPT best exclude advanced fibrosis in Asian patients with MAFLD. Metabolism: Clin Exp. 2022;128:154958

Eslam M, Wong GL, Hashem AM, Chan HL, Nielsen MJ, Leeming DJ et al. A sequential algorithm combining ADAPT and liver stiffness can stage metabolic-associated fatty liver disease in hospital-based and primary care patients. Am J Gastroenterol. 2021;116:984-993 2021;116:984–993

Article  Google Scholar 

Younossi ZS, Newsome P, Chan W, et al. Development and validation of Agile 3+: novel FibroScan based score for the diagnosis of advanced fibrosis in patients with nonalcoholic fatty liver disease. J Hepatol. 2021;75:S205–S293.

Newsome PN, Sasso M, Deeks JJ, Paredes A, Boursier J, Chan WK et al. FibroScan-AST (FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: a prospective derivation and global validation study. Lancet Gastroenterol Hepatol. 2020;5:362–373

Article  Google Scholar 

Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73:202–209

Article  Google Scholar 

Zhou YJ, Gao F, Liu WY, Wong GL, Mahadeva S, Raihan Nik Mustapha N et al. Screening for compensated advanced chronic liver disease using refined Baveno VI elastography cutoffs in Asian patients with nonalcoholic fatty liver disease. Alimentary Pharmacol Ther. 2021;54:470–480

CAS  Article  Google Scholar 

EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016;64:1388–1402

Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatol. 2005;41:1313–1321

Article  Google Scholar 

Fukusato T, Fukushima J, Shiga J, Takahashi Y, Nakano T, Maeyama S et al. Interobserver variation in the histopathological assessment of nonalcoholic steatohepatitis. Hepatol Res. 2005;33:122–127

Article  Google Scholar 

Bedossa P. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. Hepatol. 2014;60:565–575

CAS  Article  Google Scholar 

Daniels SJ, Leeming DJ, Eslam M, Hashem AM, Nielsen MJ, Krag A et al. ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis. Hepatol. 2019;69:1075–1086

CAS  Article  Google Scholar 

Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatol. 2003;38:518–526

Article  Google Scholar 

Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatol. 2006;43:1317–1325

CAS  Article  Google Scholar 

Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC et al. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatol. 2007;45:846–854

CAS  Article  Google Scholar 

Harrison SA, Oliver D, Arnold HL, Gogia S, Neuschwander-Tetri BA. Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease. Gut. 2008;57:1441–1447

CAS  Article  Google Scholar 

Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterol. 2015;149:389–397.e310

Article  Google Scholar 

Friedman SL, Ratziu V, Harrison SA, Abdelmalek MF, Aithal GP, Caballeria J et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. Hepatol. 2018;67:1754–1767

CAS  Article  Google Scholar 

Ratziu V, Harrison SA, Francque S, Bedossa P, Lehert P, Serfaty L et al. Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-α and -δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. Gastroenterol. 2016;150:1147–1159.e1145

CAS  Article  Google Scholar 

Wang TY, George J, Zheng MH. Metabolic (dysfunction) associated fatty liver disease: more evidence and a bright future. Hepatobiliary Surg Nutr. 2021;10:849–852

Article  Google Scholar 

Hsu C, Caussy C, Imajo K, Chen J, Singh S, Kaulback K et al. Magnetic Resonance vs Transient Elastography Analysis of Patients With Nonalcoholic Fatty Liver Disease: A Systematic Review and Pooled Analysis of Individual Participants. Clin Gastroenterol Hepatol. 2019;17:630–637.e638

Article  Google Scholar 

Noureddin M, Truong E, Gornbein JA, Saouaf R, Guindi M, Todo T et al. MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. J Hepatol. 2022;76:781–787

Article  Google Scholar 

Imajo K, Kessoku T, Honda Y, Tomeno W, Ogawa Y, Mawatari H et al. Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. Gastroenterol. 2016;150:626–637.e627

Article  Google Scholar 

Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J Gastroenterol 2018;53:819–826

CAS  Article  Google Scholar